司美格鲁肽与哮喘发作减少近四成相关联

欧洲呼吸学会近日发表的大规模真实世界研究表明，司美格鲁肽（Ozempic和Wegovy的活性成分）的使用与哮喘发作减少近40%相关联1。该研究还发现，GLP-1类药物与慢性阻塞性肺病（COPD）恶化减少20%存在关联1。

由伦敦帝国理工学院呼吸流行病学临床副教授Chloe Bloom领导的研究分析了来自英国的电子医疗记录，每项平行研究涉及20,000至22,000人1。该研究成果在巴塞罗那举行的欧洲呼吸学会大会上提交1。研究人员指出，GLP-1药物可能具有意想不到的呼吸系统益处，但需要临床试验来确认这些发现1。

然而，Bloom强调"这些结果不足以特别推荐这些药物作为哮喘或COPD的治疗方法"1。研究建议在当前处方指南之外，不应特别为肺部疾病开始使用GLP-1受体激动剂1。

A large-scale real-world study presented by the European Respiratory Society has found that semaglutide, the active ingredient in Ozempic and Wegovy, is associated with a nearly 40% reduction in asthma attacks 1. The research, led by Professor Chloe Bloom, a clinical associate professor of respiratory epidemiology at Imperial College London, also identified a 20% decrease in chronic obstructive pulmonary disease (COPD) exacerbations among GLP-1 receptor agonist users 1.

The study analyzed electronic health records from the United Kingdom, with each parallel analysis involving between 20,000 and 22,000 individuals 1. Findings were presented at the European Respiratory Society congress in Barcelona 1. However, researchers emphasized caution about these results. "These findings are insufficient to specifically recommend these drugs as a treatment for asthma or COPD," Bloom stated 1. The study recommended that GLP-1 receptor agonists should not be initiated specifically for lung diseases outside current prescribing guidelines 1.